{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:37Z","timestamp":1786980217817,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AR070620"],"award-info":[{"award-number":["R21AR070620"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56DK084045"],"award-info":[{"award-number":["R56DK084045"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Tissue Res"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00441-020-03358-8","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T12:26:21Z","timestamp":1609935981000},"page":"527-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of an SGLT2-loss of function mutation on renal architecture, histology, and glucose homeostasis"],"prefix":"10.1007","volume":"384","author":[{"given":"Corey B.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Mussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgilius","family":"Cornea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Thrailkill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Fowlkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-9241","authenticated-orcid":false,"given":"Iuliana","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"3358_CR1","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.2337\/db13-0604","volume":"62","author":"MA Abdul-Ghani","year":"2013","unstructured":"Abdul-Ghani MA, DeFronzo RA, Norton L (2013) Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30\u201350% of filtered glucose load in humans. Diabetes 62:3324\u20133328","journal-title":"Diabetes"},{"key":"3358_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2337\/db19-0770","volume":"69","author":"M Alatrach","year":"2020","unstructured":"Alatrach M, Laichuthai N, Martinez R, Agyin C, Ali AM, Al-Jobori H, Lavynenko O, Adams J, Triplitt C, DeFronzo R, Cersosimo E, Abdul-Ghani M (2020) Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors. Diabetes 69:681\u2013688","journal-title":"Diabetes"},{"key":"3358_CR3","doi-asserted-by":"publisher","first-page":"e0157672","DOI":"10.1371\/journal.pone.0157672","volume":"11","author":"K Atageldiyeva","year":"2016","unstructured":"Atageldiyeva K, Fujita Y, Yanagimachi T, Mizumoto K, Takeda Y, Honjo J, Takiyama Y, Abiko A, Makino Y, Haneda M (2016) Sodium-glucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice. PLoS ONE 11:e0157672","journal-title":"PLoS ONE"},{"key":"3358_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21:512\u2013517","journal-title":"Nat Med"},{"key":"3358_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","volume":"1","author":"J Chen","year":"2010","unstructured":"Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN (2010) Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes therapy\u202f: research, treatment and education of diabetes and related disorders 1:57\u201392","journal-title":"Diabetes therapy : research, treatment and education of diabetes and related disorders"},{"key":"3358_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","volume":"26","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E (2017) Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 26:27\u201338","journal-title":"Cell Metab"},{"key":"3358_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499\u2013508","journal-title":"J Clin Invest"},{"key":"3358_CR8","doi-asserted-by":"crossref","unstructured":"Fishman B, Shlomai G, Twig G, Derazne E, Tenenbaum A, Fisman EZ, Leiba A, Grossman E (2019) Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents. Cardiovascular Diabetology 18:124","DOI":"10.1186\/s12933-019-0929-7"},{"key":"3358_CR9","doi-asserted-by":"publisher","first-page":"26428","DOI":"10.1038\/srep26428","volume":"6","author":"LA Gallo","year":"2016","unstructured":"Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, Harvie BM, Kinneally TL, Yeh SM, McCarthy DA, Koepsell H, Vallon V, Pollock C, Panchapakesan U, Forbes JM (2016) Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db\/db mice. Sci Rep 6:26428","journal-title":"Sci Rep"},{"key":"3358_CR10","doi-asserted-by":"publisher","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","volume":"307","author":"F Gembardt","year":"2014","unstructured":"Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307:F317-325","journal-title":"Am J Physiol Renal Physiol"},{"key":"3358_CR11","doi-asserted-by":"publisher","first-page":"C348","DOI":"10.1152\/ajpcell.00115.2012","volume":"303","author":"C Ghezzi","year":"2012","unstructured":"Ghezzi C, Wright EM (2012) Regulation of the human Na+-dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol 303:C348-354","journal-title":"Am J Physiol Cell Physiol"},{"key":"3358_CR12","doi-asserted-by":"publisher","first-page":"e00239","DOI":"10.1002\/prp2.239","volume":"4","author":"T Hatanaka","year":"2016","unstructured":"Hatanaka T, Ogawa D, Tachibana H, Eguchi J, Inoue T, Yamada H, Takei K, Makino H, Wada J (2016) Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect 4:e00239","journal-title":"Pharmacol Res Perspect"},{"key":"3358_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1590\/s1677-5538.ibju.2015.0423","volume":"43","author":"WH Huang","year":"2017","unstructured":"Huang WH, Chang CH, Huang CP, Wu HC, Hsieh IP (2017) The percentage of resected and ischemic volume determined by a geometric model is a significant predictor of renal functional change after partial nephrectomy. Int Braz J Urol 43:80\u201386","journal-title":"Int Braz J Urol"},{"key":"3358_CR14","doi-asserted-by":"publisher","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","volume":"300","author":"CS Hummel","year":"2011","unstructured":"Hummel CS, Lu C, Loo DDF, Hirayama BA, Voss AA, Wright EM (2011) Glucose transport by human renal Na+\/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300:C14\u2013C21","journal-title":"Am J Physiol Cell Physiol"},{"key":"3358_CR15","doi-asserted-by":"publisher","first-page":"e108941","DOI":"10.1371\/journal.pone.0108941","volume":"9","author":"M Jiang","year":"2014","unstructured":"Jiang M, Wang Q, Karasawa T, Koo JW, Li H, Steyger PS (2014) Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides. PLoS ONE 9:e108941","journal-title":"PLoS ONE"},{"key":"3358_CR16","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/db10-1328","volume":"60","author":"MJ Jurczak","year":"2011","unstructured":"Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, Zhao X, Moeckel GW, Samuel VT, Whaley JM, Shulman GI, Kibbey RG (2011) SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60:890\u2013898","journal-title":"Diabetes"},{"key":"3358_CR17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00125-019-4849-6","volume":"62","author":"RE Kuhre","year":"2019","unstructured":"Kuhre RE, Ghiasi SM, Adriaenssens AE, Wewer Albrechtsen NJ, Andersen DB, Aivazidis A, Chen L, Mandrup-Poulsen T, Orskov C, Gribble FM, Reimann F, Wierup N, Tyrberg B, Holst JJ (2019) No direct effect of SGLT2 activity on glucagon secretion. Diabetologia 62:1011\u20131023","journal-title":"Diabetologia"},{"key":"3358_CR18","first-page":"4364","volume":"19","author":"S Li","year":"2019","unstructured":"Li S, Yang Y, Huang L, Kong M, Yang Z (2019) A novel compound heterozygous mutation in SLC5A2 contributes to familial renal glucosuria in a Chinese family, and a review of the relevant literature. Mol Med Rep 19:4364\u20134376","journal-title":"Mol Med Rep"},{"key":"3358_CR19","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","volume":"61","author":"BC Lupsa","year":"2018","unstructured":"Lupsa BC, Inzucchi SE (2018) Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 61:2118\u20132125","journal-title":"Diabetologia"},{"key":"3358_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1681\/ASN.2010080888","volume":"22","author":"JP Ly","year":"2011","unstructured":"Ly JP, Onay T, Sison K, Sivaskandarajah G, Sabbisetti V, Li L, Bonventre JV, Flenniken A, Paragas N, Barasch JM, Adamson SL, Osborne L, Rossant J, Schnermann J, Quaggin SE (2011) The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol 22:113\u2013123","journal-title":"J Am Soc Nephrol"},{"key":"3358_CR21","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1038\/s41598-019-41253-7","volume":"9","author":"T Maki","year":"2019","unstructured":"Maki T, Maeno S, Maeda Y, Yamato M, Sonoda N, Ogawa Y, Wakisaka M, Inoguchi T (2019) Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: a possible role of SGLT2 in mesangial cells. Scientific Reports 9:4703","journal-title":"Scientific Reports"},{"key":"3358_CR22","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.2337\/db17-1278","volume":"67","author":"R Martinez","year":"2018","unstructured":"Martinez R, Al-Jobori H, Ali AM, Adams J, Abdul-Ghani M, Triplitt C, DeFronzo RA, Cersosimo E (2018) Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy. Diabetes 67:1182\u20131189","journal-title":"Diabetes"},{"key":"3358_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124:509\u2013514","journal-title":"J Clin Invest"},{"key":"3358_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/bph.12269","volume":"170","author":"T Nagata","year":"2013","unstructured":"Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, Nihei T, Honda K, Suzuki Y, Kawabe Y (2013) Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db\/db mice. Br J Pharmacol 170:519\u2013531","journal-title":"Br J Pharmacol"},{"key":"3358_CR25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"3358_CR26","first-page":"156","volume":"27","author":"BS Oemar","year":"1987","unstructured":"Oemar BS, Byrd DJ, Brodehl J (1987) Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clin Nephrol 27:156\u2013160","journal-title":"Clin Nephrol"},{"key":"3358_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y (2016) Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2: inhibition kinetics, sidedness of action, and transporter-associated incorporation accounting for its pharmacodynamic and pharmacokinetic features. J Pharmacol Exp Ther 358:94\u2013102","journal-title":"J Pharmacol Exp Ther"},{"key":"3358_CR28","doi-asserted-by":"crossref","unstructured":"Osataphan S, Macchi C, Singhal G, Chimene-Weiss J, Sales V, Kozuka C, Dreyfuss JM, Pan H, Tangcharoenpaisan Y, Morningstar J, Gerszten R, Patti M-E (2019) SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI Insight 4","DOI":"10.1172\/jci.insight.123130"},{"key":"3358_CR29","doi-asserted-by":"publisher","first-page":"e0146114","DOI":"10.1371\/journal.pone.0146114","volume":"11","author":"E Ottosson-Laakso","year":"2016","unstructured":"Ottosson-Laakso E, Tuomi T, Forsen B, Gullstrom M, Groop PH, Groop L, Vikman P (2016) Influence of familial renal glycosuria due to mutations in the SLC5A2 gene on changes in glucose tolerance over time. PLoS ONE 11:e0146114","journal-title":"PLoS ONE"},{"key":"3358_CR30","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M (2020) SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 43:508\u2013511","journal-title":"Diabetes Care"},{"key":"3358_CR31","doi-asserted-by":"publisher","first-page":"10029","DOI":"10.1074\/jbc.271.17.10029","volume":"271","author":"M Panayotova-Heiermann","year":"1996","unstructured":"Panayotova-Heiermann M, Loo DD, Kong CT, Lever JE, Wright EM (1996) Sugar binding to Na+\/glucose cotransporters is determined by the carboxyl-terminal half of the protein. J Biol Chem 271:10029\u201310034","journal-title":"J Biol Chem"},{"key":"3358_CR32","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s00125-012-2585-2","volume":"55","author":"HE Parker","year":"2012","unstructured":"Parker HE, Adriaenssens A, Rogers G, Richards P, Koepsell H, Reimann F, Gribble FM (2012) Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia 55:2445\u20132455","journal-title":"Diabetologia"},{"key":"3358_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/MNH.0000000000000152","volume":"24","author":"SB Poulsen","year":"2015","unstructured":"Poulsen SB, Fenton RA, Rieg T (2015) Sodium-glucose cotransport. Curr Opin Nephrol Hypertens 24:463\u2013469","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3358_CR34","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","volume":"304","author":"DR Powell","year":"2013","unstructured":"Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A, Buhring L, Platt KA, Vogel P, Brommage R, Shadoan MK, Sands AT, Zambrowicz B (2013) Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 304:E117-130","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3358_CR35","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","volume":"54","author":"H Rahmoune","year":"2005","unstructured":"Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427\u20133434","journal-title":"Diabetes"},{"key":"3358_CR36","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306:F188-193","journal-title":"Am J Physiol Renal Physiol"},{"key":"3358_CR37","doi-asserted-by":"publisher","first-page":"e89977","DOI":"10.1371\/journal.pone.0089977","volume":"9","author":"PV Roder","year":"2014","unstructured":"Roder PV, Geillinger KE, Zietek TS, Thorens B, Koepsell H, Daniel H (2014) The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS ONE 9:e89977","journal-title":"PLoS ONE"},{"key":"3358_CR38","doi-asserted-by":"publisher","first-page":"C1174","DOI":"10.1152\/ajpcell.00450.2011","volume":"302","author":"I Sabolic","year":"2012","unstructured":"Sabolic I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, Ljubojevic M, Brzica H, Sebastiani A, Thal SC, Sauvant C, Kipp H, Vallon V, Koepsell H (2012) Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 302:C1174-1188","journal-title":"Am J Physiol Cell Physiol"},{"key":"3358_CR39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s13340-018-0367-x","volume":"9","author":"H Satoh","year":"2018","unstructured":"Satoh H (2018) Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control. Diabetol Int 9:212\u2013214","journal-title":"Diabetol Int"},{"key":"3358_CR40","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1194\/jlr.M074427","volume":"58","author":"D Scerbo","year":"2017","unstructured":"Scerbo D, Son NH, Sirwi A, Zeng L, Sas KM, Cifarelli V, Schoiswohl G, Huggins LA, Gumaste N, Hu Y, Pennathur S, Abumrad NA, Kershaw EE, Hussain MM, Susztak K, Goldberg IJ (2017) Kidney triglyceride accumulation in the fasted mouse is dependent upon serum free fatty acids. J Lipid Res 58:1132\u20131142","journal-title":"J Lipid Res"},{"key":"3358_CR41","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2337\/diabetes.52.7.1649","volume":"52","author":"P She","year":"2003","unstructured":"She P, Burgess SC, Shiota M, Flakoll P, Donahue EP, Malloy CR, Sherry AD, Magnuson MA (2003) Mechanisms by which liver-specific PEPCK knockout mice preserve euglycemia during starvation. Diabetes 52:1649\u20131654","journal-title":"Diabetes"},{"key":"3358_CR42","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.diabet.2017.04.002","volume":"43","author":"A Solini","year":"2017","unstructured":"Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, Dotta F (2017) Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes Metab 43:512\u2013520","journal-title":"Diabetes Metab"},{"key":"3358_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2018.10.009","volume":"19","author":"T Suga","year":"2019","unstructured":"Suga T, Kikuchi O, Kobayashi M, Matsui S, Yokota-Hashimoto H, Wada E, Kohno D, Sasaki T, Takeuchi K, Kakizaki S, Yamada M, Kitamura T (2019) SGLT1 in pancreatic alpha cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab 19:1\u201312","journal-title":"Mol Metab"},{"key":"3358_CR44","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.1152\/ajpendo.00086.2017","volume":"313","author":"L Tang","year":"2017","unstructured":"Tang L, Wu Y, Tian M, Sjostrom CD, Johansson U, Peng XR, Smith DM, Huang Y (2017) Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab 313:E563-e576","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3358_CR45","doi-asserted-by":"publisher","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","volume":"9","author":"N Terami","year":"2014","unstructured":"Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, Eguchi J, Horiguchi CS, Nishii N, Yamada H, Takei K, Makino H (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PLoS ONE 9:e100777","journal-title":"PLoS ONE"},{"key":"3358_CR46","doi-asserted-by":"publisher","first-page":"115254","DOI":"10.1016\/j.bone.2020.115254","volume":"133","author":"KM Thrailkill","year":"2020","unstructured":"Thrailkill KM, Bunn RC, Uppuganti S, Ray P, Garrett K, Popescu I, Pennings JS, Fowlkes JL, Nyman JS (2020) Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone. Bone 133:115254","journal-title":"Bone"},{"key":"3358_CR47","unstructured":"Tomisato Wataru BK, Murray Anne, Beutler Bruce. Record for Jimbee, updated 2018\u201303\u201309. MUTAGENETIX (TM), B. Beutler and colleagues. Center for the Genetics of Host Defense, UT Southwestern, Dallas, TX. Accessed 2019\u201309\u201330. https:\/\/mutagenetix.utsouthwestern.edu"},{"key":"3358_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104\u2013112","journal-title":"J Am Soc Nephrol"},{"key":"3358_CR49","doi-asserted-by":"publisher","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","volume":"304","author":"V Vallon","year":"2013","unstructured":"Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T (2013) Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304:F156-167","journal-title":"Am J Physiol Renal Physiol"},{"key":"3358_CR50","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"Volker Vallon","year":"2014","unstructured":"Volker Vallon, Maria Gerasimova, Michael A. Rose, Takahiro Masuda, Joseph Satriano, Eric Mayoux, Hermann Koepsell, Scott C. Thomson, Timo Rieg, (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. American Journal of Physiology-Renal Physiology 306 (2):F194-F204","journal-title":"American Journal of Physiology-Renal Physiology"},{"key":"3358_CR51","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","volume":"467","author":"I Vrhovac","year":"2015","unstructured":"Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, Radovic N, Jadrijevic S, Aleksic I, Walles T, Sauvant C, Sabolic I, Koepsell H (2015) Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467:1881\u20131898","journal-title":"Pflugers Arch"},{"key":"3358_CR52","doi-asserted-by":"crossref","unstructured":"Wang D, Luo Y, Wang X, Orlicky DJ, Myakala K, Yang P, Levi M (2018a) The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in western diet induced obesity mice. Int J Mol Sci 19","DOI":"10.3390\/ijms19010137"},{"key":"3358_CR53","doi-asserted-by":"crossref","unstructured":"Wang S, Zhao X, Zhang R, Wang C, Han Y, Shao L (2019) Identification of ten novel SLC5A2 mutations and determination of the renal threshold for glucose excretion in Chinese patients with familial renal glucosuria. Clin Chim Acta 490:102\u2013106","DOI":"10.1016\/j.cca.2018.12.024"},{"key":"3358_CR54","doi-asserted-by":"crossref","unstructured":"Wang T, Bu CH, Hildebrand S, Jia G, Siggs OM, Lyon S, Pratt D, Scott L, Russell J, Ludwig S, Murray AR, Moresco EMY, Beutler B (2018b) Probability of phenotypically detectable protein damage by ENU-induced mutations in the Mutagenetix database. Nat Commun 9:441","DOI":"10.1038\/s41467-017-02806-4"},{"key":"3358_CR55","doi-asserted-by":"crossref","unstructured":"Wang T, Zhan X, Bu CH, Lyon S, Pratt D, Hildebrand S, Choi JH, Zhang Z, Zeng M, Wang KW, Turer E, Chen Z, Zhang D, Yue T, Wang Y, Shi H, Wang J, Sun L, SoRelle J, McAlpine W, Hutchins N, Zhan X, Fina M, Gobert R, Quan J, Kreutzer M, Arnett S, Hawkins K, Leach A, Tate C, Daniel C, Reyna C, Prince L, Davis S, Purrington J, Bearden R, Weatherly J, White D, Russell J, Sun Q, Tang M, Li X, Scott L, Moresco EM, McInerney GM, Karlsson Hedestam GB, Xie Y, Beutler B (2015) Real-time resolution of point mutations that cause phenovariance in mice. Proc Natl Acad Sci U S A 112:E440-449","DOI":"10.1073\/pnas.1423216112"},{"key":"3358_CR56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323\u2013334","journal-title":"N Engl J Med"},{"key":"3358_CR57","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1242\/jeb.200.2.287","volume":"200","author":"EM Wright","year":"1997","unstructured":"Wright EM, Hirsch JR, Loo DD, Zampighi GA (1997) Regulation of Na+\/glucose cotransporters. J Exp Biol 200:287\u2013293","journal-title":"J Exp Biol"},{"key":"3358_CR58","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733\u2013794","journal-title":"Physiol Rev"},{"key":"3358_CR59","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00439-010-0927-z","volume":"129","author":"L Yu","year":"2011","unstructured":"Yu L, Lv JC, Zhou XJ, Zhu L, Hou P, Zhang H (2011) Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients. Hum Genet 129:335\u2013344","journal-title":"Hum Genet"},{"key":"3358_CR60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12882-016-0244-4","volume":"17","author":"L Yu","year":"2016","unstructured":"Yu L, Xu Q, Hou P, Zhang H (2016) Decreased expression and function of sodium-glucose co-transporter 2 from a novel C-terminal mutation: a case report. BMC Nephrol 17:31","journal-title":"BMC Nephrol"}],"container-title":["Cell and Tissue Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-020-03358-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00441-020-03358-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-020-03358-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T08:07:39Z","timestamp":1666858059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00441-020-03358-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3358"],"URL":"https:\/\/doi.org\/10.1007\/s00441-020-03358-8","relation":{},"ISSN":["0302-766X","1432-0878"],"issn-type":[{"value":"0302-766X","type":"print"},{"value":"1432-0878","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Experiments on animals were approved by the local Institutional Animal Care and Use Committee (IACUC# 2015-2293) of the University of Kentucky, Lexington KY. All applicable international, national and\/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}}]}}